Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "liposomal doxorubicin" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-8 z 8
    Tytuł:
    Efficacy and safety of liposomal doxorubicin in a patient treated for metastatic breast cancer
    Autorzy:
    Streb, Joanna
    Słowik, Agnieszka
    Powiązania:
    https://bibliotekanauki.pl/articles/1065206.pdf
    Data publikacji:
    2015
    Wydawca:
    Medical Education
    Tematy:
    breast cancer
    cardiotoxicity
    liposomal doxorubicin
    Opis:
    Liposomal doxorubicin is a newer form of chemotherapeutic agents that, due to its own special properties, preferably accumulates in cancer tissue. On the other hand, it shows lower affinity to cardiomyocytes and in this way is less cardiotoxic. As a result of that, there is the possibility to use liposomal form of doxorubicin until disease progression or chemotherapy intolerance in palliative setting, without treatment cessation after reaching the maximum cumulative dose of conventional doxorubicin. In this article we describe the case of a female patient diagnosed with breast cancer who was primary treated with adjuvant treatment, including chemotherapy and in whom a disease recurrence occurred after seven years of observation. As a primary palliative treatment the patient received chemotherapy based on liposomal doxorubicin and cyclofosphamide with a very good tolerance. The initial response was partial remission in lungs and in mediastinal lymph nodes. During the whole course of therapy there were no pathological changes in electrocardiogram, no signs and no symptoms of congestive heart failure, and the left ventricular ejection fraction was within normal limits.
    Źródło:
    OncoReview; 2015, 5, 2; A67-70
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Liposomal doxorubicin in first line metastatic HER-2-positive breast cancer for prevention the cardiotoxicity
    Autorzy:
    Chmielowska, Ewa
    Powiązania:
    https://bibliotekanauki.pl/articles/1065040.pdf
    Data publikacji:
    2015
    Wydawca:
    Medical Education
    Tematy:
    HER-2 overexpression
    cardiotoxicity
    liposomal doxorubicin
    Opis:
    We describe a 62 year old female with metastatic HER-2-positive breast cancer, and with independent cardiovascular comorbidities. She was earlier treated with J131 therapy due to thyroid toxicity. She developed grade 2 mitral and tricuspid valvular insufficiency as a result of uncontrolled hypertension. In 2013, the patient was diagnosed with luminal B2 breast cancer with liver and bone metastases, and a large infiltration of the left breast together with the surrounding soft tissue. She was treated with liposomal doxorubicin and cyclophosphamide, with the dose of anthracycline slightly reduced to 50 mg/m2 because of the elevated liver enzymes. She was in complete remission during treatment, without any cardiac or hematologic toxicity. The treatment was prolonged to eight cycles until the liver tests returned to normal. The cumulative dose of liposomal doxorubicin amounted to 400 mg/m2 (with the maximum recommended dose of 600 mg/m2). We decided to administer the liposomal form of doxorubicin, which is less cardiotoxic than conventional doxorubicin, as first-line treatment in order to prevent cardiotoxicity in a patient who is a candidate for another cardiotoxic therapy involving trastuzumab in the future. The patient’s disease progressed 10 months following the completion of first-line therapy. There are no cardiologic contraindications to trastuzumab and there are no signs of liposomal doxorubicin-related cardiotoxicity or deterioration of the valvular insufficiency.
    Źródło:
    OncoReview; 2015, 5, 1; A11-A15
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Efficacy and safety of non-pegylated liposomal doxorubicin in metastatic breast cancer therapy
    Autorzy:
    Wójcik, Elżbieta
    Kufel-Grabowska, Joanna
    Gierba-Tomczyk, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1062503.pdf
    Data publikacji:
    2017
    Wydawca:
    Medical Education
    Tematy:
    breast cancer
    non-pegylated liposomal doxorubicin
    treatment
    Opis:
    Breast cancer is the most frequently diagnosed female cancer in Poland (over 17,500 women). Anthracyclines have become one of the most important drugs in breast cancer systemic treatment. In the treatment of metastatic disease combination chemotherapy with doxorubicin provides the objective response rate of 60–85%, and the median time of progression-free survival is about 12 months. Non-pegylated liposomal doxorubicin (NPLD) in combination with cyclophosphamide is associated with a lower risk of cardiotoxicity, higher efficacy and more favourable toxicity profile as compared with conventional anthracycline regimes. Two cases of females patients treated with NPLD described in this article demonstrate the importance of the choice of chemotherapy, professional monitoring, early detection and treatment of adverse effects. Non-pegylated liposomal doxorubicin ordained in systemic treatment of stage IV breast cancer prolongs survival and enhances the quality of life. It is a reasonable option for palliative therapy.
    Źródło:
    OncoReview; 2017, 7, 4; 162-167
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Administration of liposomal doxorubicin in patients with metastatic breast cancer and significant concomitant cardiovascular conditions
    Autorzy:
    Bryjak, Agnieszka
    Powiązania:
    https://bibliotekanauki.pl/articles/773565.pdf
    Data publikacji:
    2014
    Wydawca:
    Medical Education
    Tematy:
    NLPD
    cardiotoxicity
    conventional anthracyclines
    liposomal doxorubicin
    metastatic breast cancer
    Opis:
    A frequent dilemma faced by an oncologist about to take decision on a chemotherapeutic regime for patients with metastatic breast cancer is how to maintain balance between the expected treatment efficacy and predictable adverse events. In the case of anthracyclines what is problematic is their significant cardiotoxicity, in particular with reference to patients previously treated with them as part of adjuvant therapy. A relatively new method is replacement of conventional doxorubicin with its non-pegylated form, encapsulated in liposomes, which is capable of minimizing the side effects without compromising its therapeutic index. The present article discusses three cases of patients treated with non-pegylated liposomal doxorubicin (NPLD) as first-line chemotherapy administered for metastatic breast cancer. In all three cases considerable clinical improvement was observed, involving remission of pathological lesions and good quality of life.
    Źródło:
    OncoReview; 2014, 4, 4; A148-A154
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Non-pegylated liposomal doxorubicin plus capecitabine as first-line treatment in metastatic breast cancer
    Autorzy:
    Plecka, Piotr
    Powiązania:
    https://bibliotekanauki.pl/articles/1064811.pdf
    Data publikacji:
    2016
    Wydawca:
    Medical Education
    Tematy:
    breast cancer
    chemotherapy
    new regimen
    non-pegylated liposomal doxorubicin
    Opis:
    Purpose: To determine the toxicity and efficacy profile of non-pegylated doxorubicin in combination with capecitabine administered according to LipAX regimen. Materials and methods: The analysis included 5 female patients undergoing first-line treatment for metastatic breast cancer. Patients received non-pegylated doxorubicin intravenously and oral capecitabine at usual doses used for monotherapy, until disease progression or unacceptable toxicity. Results: Patients received a total of 26 complete treatment cycles according to LipAX regimen. During treatment, 15 toxicities occurred, including 7 adverse events with grade 3 severity. Only two haematological toxicities were observed, and the other 13 were of a non-haematological nature. Only one patient experienced no adverse events. Apart from symptomatic treatment, the capecitabine dose was reduced twice and the non-pegylated doxorubicin once. Positive clinical outcomes were observed in 4 patients, and disease progression was reported in the case of 1 patient in the course of the treatment. The median time to disease progression was 10.4 months, and the median overall survival was 34.2 months. During the 54-month follow-up, 4 of the patients died. The surviving patient continues treatment. Conclusions: Therapy according to the LipAX regimen was relatively well tolerated, however, since the majority of patients discontinued treatment due to adverse events, and not disease progression, an adequate reduction in the cytostatic doses should be considered. The use of the LipAX regimen may contribute to the achievement of long-term remission in some patients, a fact that encourages further studies on this form of therapy.
    Źródło:
    OncoReview; 2016, 6, 4; A193-198
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Therapy with liposomal doxorubicin in patients with advanced breast cancer after treatment with classical doxorubicin
    Autorzy:
    Kufel-Grabowska, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1065267.pdf
    Data publikacji:
    2015
    Wydawca:
    Medical Education
    Tematy:
    breast cancer
    complications of oncological therapy
    non-pegylated liposomal doxorubicin
    Opis:
    Breast cancer is the most common female cancer in the world and in Poland. The improvement of diagnostic and therapeutic methods has led to patients’ longer life expectancy. It has also made breast cancer a chronic disease, increasing the risk of late side effects of oncological therapy. More cardiovascular diseases are diagnose in patients over 65 with an oncological history than in those without it and therefore much effort must be made to maximise effectiveness of the therapy with as few side effects as possible. The article presents two breast cancer patients treated with big doses of liposomal doxorubicin with a good response and almost no side effects.
    Źródło:
    OncoReview; 2015, 5, 3; A103-108
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Off-label drug use in breast cancer therapy
    Autorzy:
    Jankowski, Tomasz
    Urbaniak, Monika
    Powiązania:
    https://bibliotekanauki.pl/articles/773466.pdf
    Data publikacji:
    2017
    Wydawca:
    Medical Education
    Tematy:
    breast cancer
    capecitabine
    chemotherapy
    liposomal doxorubicin
    metronomic vinorelbine
    off-label
    Opis:
    Breast cancer is one of the most common malignancies across the world, including Poland. Chemotherapy plays an important part in the treatment of the disease. Most of the available chemotherapy drugs and regimens have undergone randomized clinical studies and have been registered for that specific indication. However, a number of drugs are used in an off-label manner, i.e. outside the officially approved product specifications. The paper discusses the use of several off-label therapies in breast cancer in order to demonstrate that such treatment may be well-grounded and indeed turns out beneficial in many cases. It describes the use of liposomal doxorubicin in pre- and post-operative treatment, capecitabine for incomplete efficacy of preoperative treatment, and the administration of metronomic vinorelbine. Moreover, the paper is aimed at demonstrating the legal basis and the principles of marketing authorization of off-label drug use.
    Źródło:
    OncoReview; 2017, 7, 2; 83-87
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The young breast cancer patient therapy – new opportunities, new challenges
    Autorzy:
    Załuska-Kusz, Joanna
    Kufel-Grabowska, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1035689.pdf
    Data publikacji:
    2019
    Wydawca:
    Medical Education
    Tematy:
    breast cancer in young patient
    metastatic disease
    non-pegylated liposomal doxorubicin
    ribociclib
    Opis:
    The paper describes the case of a 31-year-old female patient with breast cancer with the abdominal metastases. This disease in young people usually has a more aggressive biological subtype, which significantly worsens the prognosis. In this patient aggressive treatment was used. It was effective and did not cause severe or long-term complications.
    Źródło:
    OncoReview; 2019, 9, 2; 51-54
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-8 z 8

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies